Efficacy of Ustekinumab combined with partial enteral nutrition in Crohn’s disease (opens in new tab)

BackgroundUstekinumab (UST) has emerged as an effective biological therapy for Crohn’s disease (CD), yet many patients experience suboptimal long-term mucosal healing. Partial enteral nutrition (PEN) may enhance treatment outcomes by reducing intestinal inflammation and improving nutritional status. However, evidence regarding the combined use of UST and PEN remains limited. This study aims to investigate the effect of UST combined with PEN on therapeutic efficacy in CD patients.MethodsWe con...